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ABSTRACT 
Objective: To develop a simple, rapid, precise and reproducible liquid chromatographic method for the estimation meropenem (MEP) and 
vaborbactam (VAB) in bulk and pharmaceutical formulation and study of the stability of the drugs in different stressed conditions. 
Methods: The chromatographic separation was achieved on a Kromasil C18 column (250 × 4.6 mm) using a mobile phase composition of 
acetonitrile and 10 mmol phosphate buffer (pH 3.50) in a ratio 30:70 v/v, pumped at a flow rate of 1.0 ml/min with UV detection set at 260 nm.  
Results: Symmetrical and sharp peaks of MEP and VAB were obtained at retention times of 2.29 and 3.10 min, respectively. The chromatographic 
method was validated for linearity, limits of detection and quantitation, precision, accuracy, system suitability and robustness. Calibration curves 
were obtained in the concentration ranges of 25–150 μg/ml for MEP and VAB. Stability tests done through the exposure of the analytes solution for 
different stress conditions and the obtained results indicate no interference of degradants with HPLC method. 
Conclusion: The proposed method has been found to be selective, precise, linear, accurate, and sensitive. The method can be successfully applied to 
the assay determination of bulk drugs and combined dosage forms for routine analysis. 
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The threat of antimicrobial resistance is rising globally at alarming 
rates, leading to a major hazard to patients. The Centers for Disease 
Control and Prevention (CDC) has categorized carbapenem-resistant 
Enterobacteriaceae (CRE) as the highest warning level of ‘urgent’ 
and the WHO has deemed CRE as one of the three vital pathogens in 
need of new antimicrobial options [1-3]. The mortality rates in 
patients with invasive infections which are caused by CRE have 
historically been reported to be as high as 70%. Therefore, the 
discovery and development of new regimen options are critical 
public health priorities, underlining the need for newer therapies for 
treating gram-negative pathogens. Meropenem–Vaborbactam 
(Vabomere™), a carbapenem and first-in-class boronic acid-based β-
lactamase inhibitor combination product recently approved by the 
FDA for the treatment of complicated urinary tract infections, 
including pyelonephritis [4]. 
Meropenem (MEP), (4R,5S,6S)-3-(((3S,5S)-5-(dimethylcarbamoyl) 
pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-
azabicyclo [3.2.0] hept-2-ene-2-carboxylic acid is a carbapenem 
class of antibiotics which have in common a carbon atom substituted 
for sulfur at place 1 and an unsaturated bond between C2 and C3 of 
the familiar penicillin nucleus (fig. 1a) [5]. The basic dimethyl-
carbamoylpyrrolidinethio side chain at C2 on MEP enhances activity 
against gram-negative organisms. Carbapenems exert their 
bactericidal action through penicillin-binding proteins (PBPs) with 
subsequent inhibition of cell wall synthesis. TheMEP may give a 
stronger antibiotic backbone compared to cephalosporins when 
combined with carbapenemase inhibitors.  
Vaborbactam (VAB), (3R, 6S)-2-hydroxy-3-[[2-(2-thienyl) acetyl] 
amino]-1, 2-oxaborinane-6acetic acid is a novel non-β-lactam, cyclic 
boronic acid inhibitor of β-lactamases, based on a cyclic boronic acid 
pharmacophore (fig. 1b)[5]. It has mainly potent action against 
Klebsiella pneumoniae carbapenemase (KPC). The cyclic boronate 
ester was designed to configure the structure in a preferred 
conformation to selectively enhance substrate activity against beta-
lactamases. The potency of beta-lactamase inhibitor activity has 
increased by the addition of a 2-thienyl acetyl group in the structure 
of VAB [6]. The VAB largely has an action in molecular class A and C 
β-lactamase inhibitors, which also incorporate imipenem-resistant 
and Serratia marcescens enzyme [7]. The structures of MEP and VAB 
are shown in fig. 1. 
 
  
CDC. Antibiotic Resistance Threats in the United States, 2013. http://www. cdc. gov/drug resistance/threat-report-2013/pdf/ar-threats-2013-508. p 
Fig. 1: Chemical structures of (a) MEP and (b) VAB 
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The Code of Federal Regulations (CFR) 311.165c explicitly states 
that “the accuracy, sensitivity, specificity, and reproducibility of test 
methods employed by the firm shall be established and 
documented”. The parameters performed for the development of 
analytical method validation can be used to establish the quality, 
consistency and reliability of analytical results. The combination 
MEP and VAB introduced as an injection, for intravenous use. The 
method used in the formulation of drug delivery system (DDS) 
undergoes into different processes such as solvent evaporation or 
solvent removal techniques may result in degradation of the drug 
content. The method validation of MEP and VAB has to be performed 
that it could attain at most precise and accurate therapeutic efficacy 
by the techniques and procedure of formulation is potential in 
resulting desired therapeutic effect.  
Numerous analytical methods have been reported for the analysis of 
MEP in single or with the combination of other drugs in 
pharmaceutical formulations and several biological fluids, including 
human plasma using different sample preparation procedures: 
precipitation, liquid-or solid-phase extraction, generally followed by 
liquid chromatography coupled to UV detection or mass detection 
[8-14]. Spectrophotometric methods were also reported for the 
determination of MEP [15-16]. However, no stability indicating the 
method is available for simultaneous estimation of MEP and VAB in 
a combined pharmaceutical dosage form. Thus, the purpose of the 
present study was to develop and validate the Rp-HPLC method for 
the estimation of pure MEP and VAB, also the drug content of MEP 
and VAB in a pharmaceutical formulation as per ICH guidelines.  
MATERIALS AND METHODS 
Chemicals and reagents 
Pure active pharmaceutical ingredients, MEP and VAB, were kindly 
supplied by Aurobindo Pharma Ltd. (Telangana, India). MEP and 
VAB Injection (VABOMERE) Manufactured by Facta Farmaceutici. 
Acetonitrile and methanol of HPLC grade were procured from Merck 
Specialties Pvt. Ltd. (Mumbai, India). AR grade Potassium 
dihydrogen phosphate and ortho-phosphoric acid were purchased 
from Spectrochem Pvt. Ltd. HPLC grade water was obtained by using 
a Millipore Milli-Q water purification system (Millipore, Milford, 
USA). 
Instrumentation 
The chromatographic analysis was carried out on the Waters HPLC 
Alliance 2695 separating module using photodiode array detector 
(waters 2998) with autosampler and column oven. The instrument 
was controlled by Empower 2 software installed with equipment for 
data collection and acquisition. UV-VIS spectrophotometer PG 
Instruments T60 with UV win 6 Software was used for measuring 
the absorbance of MEP and VAB solutions. A Kromasil C18 250 x 4.6 
mm, 5µ analytical column was used.  
Chromatographic conditions 
The mobile phase consisted of buffer and acetonitrile (70:30 v/v). 
The buffer used in the mobile phase contained 10 mmol potassium 
dihydrogen phosphate, pH adjusted to 3.50±0.02 with ortho-
phosphoric acid, filtered through 0.45 µm nylon filter and degassed 
in ultrasonic bath prior to use. Measurements were made with an 
injection of volume 10 μL and UV detection at 260 nm. All analyses 
were performed at ambient temperature. 
Standard and sample solutions preparation 
Standard stock solution 
The standard solution was prepared by dissolving the drugs in the 
acetonitrile and diluting to the required concentration. The diluent 
water: acetonitrile (50:50 v/v) was used as a solvent system. 
Accurately weighed 1000 mg of dry powder (for injection) and 
transferred to 500 ml volumetric flask, to this 5 ml of acetonitrile 
was added and degassed in the ultrasonic bath. Volume was made 
up to 500 ml with diluents and filtered through a 0.45 µm nylon 
filter to get a solution of 2000µg/ml of each drug. 
Preparation of sample solutions 
5 ml of filtered sample stock solution was transferred to a 100 ml 
volumetric flask and filled the volume up to the mark with diluent to 
get a solution of concentration 100µg/ml of each drug. 
Method validation 
The optimized chromatographic conditions were validated in 
accordance with the ICH guidelines of Validation of Analytical 
Procedure: Q2 (R1) by evaluating the linearity, range, specificity, 
precision, accuracy, limit of detection (LOD), limit of quantification 
(LOQ), robustness and system suitability parameters. To assess the 
linearity and range of the developed method, six different mix 
standard concentrations (25, 50, 75, 100, 125 and 150 µg/ml) of 
MEP and VAB were prepared. The accuracy and precision were 
calculated by performing the assay of samples (spiked placebos) 
prepared at three concentration levels of 50%, 100% and 150% of 
the standard concentration, with three replicates for each 
concentration. The % recovery and %RSD were calculated for each 
of the replicate samples. The limit of detection (LOD) and limit of 
quantification (LOQ) of the proposed method were determined by 
the standard deviation of the response (σ) and slope approach as 
defined in ICH guidelines. The LOD was calculated using the formula 
3.3*σ/slope, and the LOQ was calculated using the formula 
10*σ/slope. The robustness of the method was established by the 
study of the effect of small modification of method parameters such 
as flow rate, the percentage of a buffer in the mobile phase and 
column oven temperature. The ruggedness of the method was tested 
by studying the effect of elapsed assay times and by an analyst on 
the method performance [17-18]. 
Forced degradation study 
To evaluate the stability-indicating properties and specificity of the 
method, Forced degradation studies were carried out on MEP and 
VAB. Forced degradation was performed by exposing the drug 
substance and drug product to different stress conditions. The 
conditions illustrated in table 1 were followed in the stress study 
protocol. Stressed samples were analysed periodically and the 
presence of related peaks, retention time and peak purity for the 
active ingredients was checked [19-21]. 
 
Table 1: Forced degradation conditions 
Stress type Conditions 
Acid hydrolysis 1 mg/ml in 1 N HCl at 80 °C for 2 h 
Base hydrolysis 1 mg/ml in 2 N NaOH at 80 °C for 2 h 
Oxidative degradation 1 mg/ml in 20% H2O2 at 80 °C for 2 h 
Thermal degradation  1 mg/ml in 80 °C for 48 h 
Photo degradation Overall illumination of 200Wh/m2 at 25 °C for 7 d 
 
RESULTS AND DISCUSSION 
In present work stability indicating analytical method for the 
determination of MEP and VAB in bulk drug and injection 
formulation was developed and validated as per ICH guidelines for 
analytical method validation, Q2 (R1). 
Method development 
The main purpose of this work was to develop new stability 
indicating RP-HPLC method for estimation of MEP and VAB within a 
short run time. The mobile phases and stationary phase play an 
important role in theoretical plates, peak shape, symmetry and 
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resolution. To obtain symmetrical peaks with better resolution and 
peak purity, a variety of chromatographic conditions were 
investigated and optimized for the determination of MEP and VAB; 
such as mobile phases with different composition, pH and stationary 
phases with different packing material etc.  
The UV spectrum showed that MEP and VAB have a maximum 
absorption at 260 nm. The MEP and VAB have a high ratio of carbon 
to heteroatom and has a conjugated bond. Therefore, MEP and VAB 
can be separated on a C18 column mainly based on their overall 
hydrophobicity. Trials were made by using three kinds of columns 
(Kromosil C18, XTerra C18 and Zorbax SB-C18, column) with 
different mobile phase compositions and ratios. In all of the 
proceeding columns, broad characteristic peaks were obtained 
through using different ratios (10:90, 30:70, 50:50, 70:30, 90:10) of 
methanol/acetonitrile and water. No improvement in peak shapes 
was obtained even when the temperature of the column was 
increased to 40 °C. The theoretical plates with the mixture of 
acetonitrile or methanol with water as a mobile phase were below 
1000 which indicated poor column chromatography separation 
power. The peak shape and peak symmetry were all poor with the 
above two kinds of mixtures, which might be accredited to the low 
polarity of the mobile phase. So phosphate buffer with different 
concentration (10, 20 and 50 mmol) was used to enhance polarity of 
the mobile phase, which resulted in a narrowed peak shape. 
However, the peak shape was still not satisfactory. So acetonitrile 
was used in place of methanol.  
So, the mobile phase mixture solution of phosphate buffer (10 mmol) 
and acetonitrile (70:30, v/v) was demonstrated to be the suitable for the 
improvement of peak shape and peak symmetry. With the exception of 
the composition of mixture solution, buffer pH was also found to be 
significant in the analyte separation and method optimization. The 
impact of buffer pH on retention time was related with the ionization 
form of the solute. A series of mixture solutions with different pH values 
(3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5 and 7.0) were used to investigate the 
retention time and resolution of MEP and VAB in which the rest of 
chromatographic parameters were kept unchanged.  
Finally, the mobile phase containing phosphate buffer (10 mmol 
potassium dihydrogen phosphate) and acetonitrile in 70:30v/v ratio 
(pH 3.50±0.02, adjusted with orthophosphoric acid) was preferred 
and found to be optimal with more theoretical plates, narrow peak, 
high peak symmetry and short retention time. Based on the optimal 
mobile phase, a highly symmetrical and sharp characteristic peak of 
MEP and VAB was further obtained on a Kromasil C18 column with 
1.0 ml/min flow rate. A typical HPLC chromatogram obtained during 
simultaneous estimation of MEP and VAB is given in fig. 2. 
 
 
Fig. 2: HPLC chromatogram obtained during simultaneous separation of MEP and VAB. Chromatographic conditions: Kromasil C18 
column (150 mm × 4.6 mm, particle size 5 μ); mobile phase phosphate buffer 10 mmol potassium dihydrogen phosphate and acetonitrile 
70:30 v/v, (pH adjusted to 3.50±0.02 with orthophosphoric acid); at flow rate of 1.0 ml/min; and UV detection at 260 nm 
 
Method validation 
An optimized method must be validated before actual use. As per 
ICH guidelines for analytical method validation, Q2 (R1) the system 
suitability testing was performed. The validation studies were 
performed as given in the following sections. 
Specificity 
The specificity studies proved the no interference since no other 
peak appeared at the retention time (2.30 and 3.10 min) MEP and 
VAB. Moreover, interaction studies indicated that the analytes did 
not interact with each other and were well within the acceptable 
level 2.0% of RSD. 
Range and linearity 
Six different concentrations (25, 50, 75, 100, 125 and 150 µg/ml) of 
the mixture of MEP and VAB were prepared for linearity studies. The 
calibration curves obtained by plotting peak area against 
concentration showed a linear relationship. Calibration curves with 
corresponding residual plots of MEP and VAB were shown in fig. 3. 
The linear regression equations for MEP and VAB were found to be y 
= 4826. x+2593, and y = 4887. x+6194, respectively. The regression 
coefficient (R2) values for MEP and VAB were noted 0.999 and 0.999, 
respectively. The results confirmed that there was an excellent 
correlation existed between concentration and peak area of the drug 
within the selected concentration range. The results established the 
linearity and the reproducibility of the assay method. Regression 
characteristics of the proposed HPLC method are given in table 2. 
Precision 
The intra-day precision of the developed method was determined by 
preparing the samples of the same batch with three concentrations 
and three replicate each. The inter-day precision was also 
determined by assaying the dosage form in triplicate every day for 
three consecutive days. The low value of RSD (%) represented that 
the method is precise within the acceptance limit of 2.0%. The intra 
and inter-day precision data are given in table 3. The results showed 
good precision of the developed method. 
Accuracy 
The recovery experiments were performed by adding known 
amounts of the drugs in the placebo at three levels: 50%, 100% 
and 150% of the label claim of the marketed formulation. Three 
samples were prepared for each recovery level. The solutions 
were then analyzed and the percent recoveries were calculated 
from the calibration curve. The mean recovery values were found 
to be 99.30% and 99.83%. The results showed that there was no 
interference of excipients. The results of accuracy are shown in 
table 4. 
Kshirsagar et al. 





Fig. 3: Linearity plots for MEP (a) and VAB (b) 
 
Table 2: Linearity parameters for the MEP and VAB 
Linearity parameter MEP  VAB 
Range (%v/v) 25-150  25-150 
Slope 4826±100  4888±114 
Intercept 2594±211  6194±300 
Regression Coefficient (r2) 0.999±0.001  0.999±0.001 
 
Table 3: Precision data MEP and VAB 
Parameter MEP VAB 
Intra-day (%RSD) 0.59 0.65 
Inter-day (%RSD) 0.60 0.74 
 
Table 4: Percent recovery data of MEP and VAB 
Drug % simulated dosage nominal % Mean (n=3) ±SD  RSD (%) 
MEP 50 98.50 0.967 0.98 
VAB 50 99.58 0.662 0.66 
MEP 100 99.85 0.676 0.68 
VAB 100 99.93 0.614 0.61 
MEP 150 99.57 0.684 0.69 
VAB 150 99.98 0.532 0.53 
 
Table 5: The values of LOD and LOQ 
Drug LOD (µg/ml) LOQ (µg/ml) 
MEP 0.34 1.03 
VAB 0.44 1.32 
 
Limit of detection (LOD) and limit of quantitation (LOQ) 
The sensitivity of the method determined by LOD and LOQ. The 
LOD and LOQ for MEP and VAB were determined based on a 
signal-to-noise ratio of 3:1 and 10:1, respectively, by injecting a 
series of dilute solutions with known concentrations. The LOD for 
MEP and VAB were 0.34 and 0.44 µg/ml, respectively, whereas 
LOQ were 1.03 and 1.32 µg/ml, respectively. The values showed 
that the method is sensitive. The values of LOD and LOQ are 
summarized in table 5. 
Robustness 
The robustness of an analytical method is the capability to remain 
unaffected by minor changes in parameters. The experimental 
conditions were intentionally altered and the chromatographic 
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resolution of MEP and VAB was assessed. To study the effect of the 
organic solvent (acetonitrile) on the resolution, the concentration 
was changed 2 units on either side from 30 to 32 and 28, while other 
chromatographic conditions were kept constant. To study the effect 
of flow rate on the resolution, the flow rate was changed±0.1 units 
from 1.0 to 1.1 ml/min and 0.9 ml/min, while other conditions were 
kept constant. The resolution between MEP and VAB was not less 
than 1.5 in the study. 
Forced degradation study 
All the stress conditions applied were enough to degrade MEP and 
VAB in the pharmaceutical formulation. The results of stress studies of 
MEP and VAB are shown in table 6 and table 7, respectively. MEP and 
VAB were degraded and remained 90.87% and ~91.24% respectively 
when 1 N HCl was used at 80 °C for 2 h. The MEP and VAB were 
degraded and remained ~92.77% and ~92.84% respectively when 2 
N NaOH was used at 80 °C for 2 h. The MEP and VAB were degraded 
and remained ~94.12% and ~95.82% respectively under 20% H2O2 
at 80 °C for 2 h. The MEP and VAB were degraded and remained 
~96.17% and ~96.80% respectively under 80 °C for 4 h. The MEP and 
VAB were degraded and remained ~98.81% and ~98.13% 
respectively under overall illumination of 200 Wh/m2 at 25 °C in 
photostability chamber for 7 d. From these stress studies it was thus 
concluded that MEP and VAB were not stable in strong acidic, strong 
basic and oxidative conditions, but stable in thermal and photolytic 
conditions and developed method can be considered highly specific for 
the intended use. The chromatograms of stress studies of MEP and 





Fig. 4: (a) A typical HPLC chromatogram of a sample solution containing MEP and VAB. HPLC chromatogram of MEP and VAB obtained 
from degradation studies, (b) Acid hydrolysis (1 N HCl at 80 °C for 2 h); (c) Base hydrolysis (2 N NaOH at 80 °C for 2 h); (d) Oxidative 
degradation (20% H2O2 at 80 °C for 2 h); (e) Thermal degradation (80 °C for 48 h); (f) Photodegradation (overall illumination of 
200Wh/m2at 25 °C for 7 d) 
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Table 6: Degradation study of MEP 
Condition RT Purity angle Purity threshold  % Drug degraded 
Acid Hydrolysis 2.31 98.50 0.967 0.98 
Base Hydrolysis 2.31 99.58 0.662 0.66 
Oxidative (Peroxide) 2.30 99.85 0.676 0.68 
Thermal  2.30 99.93 0.614 0.61 
Photo (UV Light) 2.30 99.57 0.684 0.69 
 
Table 7: Degradation study of VAB 
Condition RT Purity angle Purity threshold  % Drug degraded 
Acid Hydrolysis 3.09 0.312 0.465 8.76 
Base Hydrolysis 3.11 0.597 0.649 7.16 
Oxidative (Peroxide) 3.10 0.226 0.418 4.18 
Thermal  3.10 0.128 0.315 3.20 
Photo (UV Light) 3.10 0.142 0.327 1.87 
 
System suitability parameters 
System suitability parameters were measured to make sure the 
system performance. For system suitability parameters, six 
replicates of mixed standard solution were injected.  
All critical parameters met the acceptance criteria on all days [19]. 
Parameters such as resolution, capacity factor, tailing factor, 
theoretical plate, retention volume, and asymmetry factor of the 
peaks were calculated. The results are shown in table 8. 
 
Table 8: System suitability data for MEP and VAB 
Parameters MEP VAB 
Retention time (min.) 2.29±0.03 3.09±0.02 
Injection precision RSD (%) 0.11 0.15 
Resolution - 5.70 
Tailing factor 1.22 1.25 
Theoretical plates 5540 6982 
 
CONCLUSION 
A new, simple reversed-phase HPLC method for simultaneous 
estimation of MEP and VAB was developed and validated as per ICH 
guidelines. Validation exercise proved that the HPLC method is 
linear in the proposed working range as well as accurate, precise 
and specific. The good recovery percentage of dosage form suggests 
that the excipients have no interference in the determination. The 
RSD (%) was also less than 2 show a high degree of precision of the 
method. The proposed analytical method was also found to be 
robust with respect to the flow rate and composition of the mobile 
phase. In addition, easy isocratic elution and simple extraction 
procedure offered a rapid and cost-effective analysis of the drugs. 
The developed method is reliable as well as capable of 
demonstrating and detecting any expected change in the drug 
product assay during stability studies. Peak purity for MEP and VAB 
peaks was checked indicating that they are pure from any other 
excipients or impurities or derivative materials. Thus, the method of 
analysis is reliable and qualified to exhibit and identify any expected 
change in the drug product assay during stability studies. The 
proposed method can be used for routine analysis of MEP and VAB 
in the combined dosage form and the quality control in bulk 
manufacturing as well. 
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